After NASH readout, Galmed looks to Phase III

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) gained $10.54 (150%) to $17.59 on Tuesday after it said data from the Phase IIb ARREST trial showed that once-daily oral Aramchol arachidyl amino cholanoic acid led to disease improvements in patients with non-alcoholic steatohepatitis. Galmed said the data "strongly support" a Phase III trial of

Read the full 501 word article

User Sign In